Abstract
Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.
| Original language | English |
|---|---|
| Journal | Future Oncology |
| DOIs | |
| Publication status | Published - 2019 |
Fingerprint
Cite this
Pembrolizumab in lung cancer : current evidence and future perspectives. / Palumbo, Giuliano; Carillio, Guido; Manzo, Anna; Montanino, Agnese; Sforza, Vincenzo; Costanzo, Raffaele; Sandomenico, Claudia; Manna, Carmine La; Luca, Giuseppe De; Piccirillo, Maria Carmela; Daniele, Gennaro; Cecio, Rossella De; Botti, Gerardo; Totaro, Giuseppe; Muto, Paolo; Picone, Carmine; Esposito, Giovanna; Normanno, Nicola; Morabito, Alessandro.
In: Future Oncology, 2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pembrolizumab in lung cancer
T2 - current evidence and future perspectives
AU - Palumbo, Giuliano
AU - Carillio, Guido
AU - Manzo, Anna
AU - Montanino, Agnese
AU - Sforza, Vincenzo
AU - Costanzo, Raffaele
AU - Sandomenico, Claudia
AU - Manna, Carmine La
AU - Luca, Giuseppe De
AU - Piccirillo, Maria Carmela
AU - Daniele, Gennaro
AU - Cecio, Rossella De
AU - Botti, Gerardo
AU - Totaro, Giuseppe
AU - Muto, Paolo
AU - Picone, Carmine
AU - Esposito, Giovanna
AU - Normanno, Nicola
AU - Morabito, Alessandro
PY - 2019
Y1 - 2019
N2 - Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.
AB - Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.
U2 - 10.2217/fon-2019-0073
DO - 10.2217/fon-2019-0073
M3 - Article
C2 - 31432705
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
ER -